Vera Therapeutics' Phase 3 data on atacicept sparks optimism for IgAN treatment, but competition and market challenges may ...

From a competitive standpoint, the market is becoming increasingly dynamic. New entrants like Novartis' VANRAFIA and Travere Therapeutics' FILSPARI are giving tough competition to TARPEYO/KINPEYGO.

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Novartis AG stands third among the most undervalued stocks. Novartis AG (NYSE:NVS) is a Swiss pharmaceutical leader focused on ...

Vanrafia (atrasentan) recently received FDA accelerated approval for reducing proteinuria in IgA nephropathy, marking a key advancement. Fabhalta (iptacopan), an oral treatment for C3 glomerulopathy, ...

Swiss pharma giant Novartis AGNVS reported better-than-expected results for the second quarter of 2025 and upped annual guidance for core operating income. Core earnings (excluding one-time charges) ...

Novartis is a “pure-play” innovative medicines company. We have a clear focus on four core therapeutic areas (cardiovascular-renal-metabolic, immunology, neuroscience and oncology), with multiple ...

Vanrafia (atrasentan) FDA accelerated approval for IgAN OAV101 IT US and EU submissions for SMA Votoplam Phase II PIVOT-HD study positive readout in Huntington’s disease Remibrutinib Phase II study ...

Read also: Novartis receives USFDA accelerated approval for Vanrafia for proteinuria reduction in primary IgA nephropathy Novartis stock was down more than 2% on Friday morning. The company said in a ...